MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.70760

Медицинская библиотека · European journal of neurology · 2026

Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience.

Aung Pyae, Miller Debbie, Sewell Emily, Ritter Laura Mantoan, Theochari Evangelia, Stavropoulos Ioannis, Delamont Robert, Richardson Mark P, Winston Joel S, Nashef Lina

СтатьяПеревод в очереди

Аннотация

BACKGROUND

We report a single centre experience of cannabidiol use as adjunctive treatment in adults with Lennox-Gastaut Syndrome (LGS).

METHODS

Retrospective review of adults with LGS treated with cannabidiol with clinical data collected from electronic records and caregiver standardised seizure diaries with seizure-related outcomes assessed at baseline, 6 months, and last follow-up.

RESULTS

Seventy-nine adults (median age 29 years; 40 male) were included. Median follow-up was 41 months. Four patients died unrelated to cannabidiol treatment. Sixty-seven (86%) remained on treatment at last follow-up. Across all seizure types, 59.5% achieved ≥ 50% reduction at 6 months and 67.1% at last follow-up. Among those with 'Drop Seizures' (n = 78), 50% achieved > 50% reduction at 6 months and 61.5% at last follow-up. 'Drop Seizure' responder rates were numerically higher with clobazam > 5 mg/day, but with no statistically significant dose-response relationship seen. Seizure-free days increased (baseline 5.7/month; last follow-up 12.5/month). Seizure-related hospital admissions and injuries declined. Cognitive or behavioural improvements were reported in 48 patients (60.8%); there was no statistically significant association with achieving ≥ 50% seizure reduction. Drowsiness (n = 33) was the most frequent adverse event often related to drug-drug interactions. Diarrhoea (n = 24) was more common than previously reported. Side-effects necessitated ASM adjustments in 51 patients. Fourteen were able to withdraw one or more ASMs.

CONCLUSIONS

CBD was associated with sustained effectiveness and good tolerability in adults with LGS, with high retention and improvement in seizure and other clinically meaningful outcomes. Adverse effects, mainly interaction-related, were usually managed with concomitant medication adjustments.

Для цитирования: Aung Pyae, Miller Debbie, Sewell Emily, Ritter Laura Mantoan, Theochari Evangelia, Stavropoulos Ioannis, Delamont Robert, Richardson Mark P, Winston Joel S, Nashef Lina. Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience.. European journal of neurology. 2026. DOI: 10.1111/ene.70760.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.